Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zanidatamab - BeOne Medicines/Jazz Pharmaceuticals/Zymeworks

Next Previous
Drug Profile

Zanidatamab - BeOne Medicines/Jazz Pharmaceuticals/Zymeworks

Alternative Names: JZP-598; Zani - BeOne Medicines/Jazz Pharmaceuticals Inc/Zymeworks; Zanidatamab-hrii; Ziihera; ZW 25

Latest Information Update: 10 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zymeworks
  • Developer ALX Oncology; BeOne Medicines; Jazz Pharmaceuticals Inc; Zymeworks
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; Phagocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Biliary cancer; Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Biliary cancer
  • Phase III Colorectal cancer; Gastric cancer; HER2 positive breast cancer; Oesophageal cancer
  • Phase II Endometrial cancer; Solid tumours
  • Discontinued Ovarian cancer

Most Recent Events

  • 02 Jun 2025 Updated efficacy and adverse events data from a phase II trial in Gastroesophageal adenocarcinoma released by Jazz Pharmaceuticals Inc
  • 30 May 2025 Registered for Biliary cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in China (IV)
  • 25 Apr 2025 European Medicines Agency’s (EMA) CHMP grants positive opinion for Zanidatamab for Biliary cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top